NXT Nutritionals to host ‘Spring for a Cure’ for Type 1 diabetes
HOLYOKE, Mass. NXT Nutritionals Holdings, a developer and marketer of natural sweeteners, food and beverage products, on Thursday announced that former NBA Rookie of the Year, Ralph Lee Sampson, Jr., will be making a personal appearance on behalf of NXT at the Juvenile Diabetes Research Foundation International’s “Spring for a Cure” event April 30.
“We are excited to have [Sampson] join us at the Spring for a Cure event next week,” stated Mike McCarthy, president and CEO of NXT Nutritionals. “He has been actively supporting the research and the fight for a cure for diabetes, especially since hitting close to home with one of his daughters having the disease. We want to thank him for taking this opportunity to help us educate those attending the event about our Susta Natural Sweetener.”
The “Spring for a Cure” event, of which NXT is a sponsor, is a culinary, wine and spirits tasting event featuring fine cuisine and signature products from some New York restaurants.
The event is dedicated to raising money and awareness for Type 1, or juvenile diabetes.
Biocodex appoints new VP, managing director
SAN BRUNO, Calif. Biocodex, manufacturer of Florastor and Florastor Kids probiotic supplements, on Thursday announced the appointment of Marc Rohman as VP and managing director of Biocodex, Inc., the French company’s U.S. subsidiary.
According to Nicolas Coudurier, international director of Biocodex, the U.S. market is a key priority for the company for its planned strategic expansion in the pharmaceutical arena.
“Florastor has been a tremendous success worldwide, and we feel there is great potential for the U.S. to be one of our largest footprints for this and other brands,” Coudurier said. “We’re thrilled to have someone with [Rohman’s] vast pharma expertise, not only on the marketing side, but also on the medical affairs side, to lead our foray into new U.S. product offerings.”
Prior to joining Biocodex, Rohman was part of the senior management team at FlowMedica where he was responsible for directing the company’s collaboration efforts for targeted renal therapy. While at FlowMedica, he also directed the collaborative pharma and other general business development efforts, as well as lead marketing, market development and general promotion of the company.
“Maximizing the potential of the Florastor brand is going to be a key priority for me, but at the same time, I will also be focusing on strategic alliances to build the company’s U.S. portfolio,” Rohman said. “Within the next five years or so, I’d like to see the U.S. arm of Biocodex bring at least two or more products to market.”
In addition to his work at FlowMedica, Rohman also worked for leading biotech and pharmaceutical companies, such as Scios, which was acquired by Johnson & Johnson in 2003, Mallinckrodt (now Tyco Healthcare), Boehringer Mannheim, Knoll Pharmaceuticals and Marion Labs.
Rohman holds a Bachelor of Arts degree in advertising from Michigan State University.
FDA to expand Plan B availability to 17-year-olds
ROCKVILLE, Md. The Food and Drug Administration on Wednesday informed Duramed Research, manufacturer of Plan B, that it may market the emergency contraceptive without a prescription to women age 17 years and older, following submission and approval of the appropriate application.
Currently, the emergency contraceptive Plan B is available behind the pharmacy counter for women over the age of 18, but as a prescription-only product for women 17 years old and younger.
The FDA decision came within the 30 days mandated by a federal court to permit the Plan B drug sponsor to make Plan B available to women 17 and older without a prescription.
“The government will not appeal this decision,” the FDA stated. “In accordance with the court’s order, and consistent with the scientific findings made in 2005 by the Center for Drug Evaluation and Research, FDA notified the manufacturer of Plan B informing the company that it may … market Plan B without a prescription to women 17 years of age and older.”
Plan B is manufactured by Duramed Research, which was acquired by Teva Pharmaceutical Industries in December as part of its acquisition of Barr Pharmaceuticals.